Bioscience Pharma Partners, founded in 2013, is dedicated to the research and development of drugs targeting chronic neuroinflammation in central nervous system (CNS) disorders. The company’s core mission is to advance treatments for neurodegenerative diseases by leveraging their expertise in leukotriene pathway inhibitors. They focus on conducting Phase III human clinical trials and licensing repurposed compounds, particularly those with potential anti-neuroinflammatory effects for conditions such as traumatic brain injury.

Notable figures associated with Bioscience Pharma Partners include a team of experienced scientists and strategic advisors who contribute to the company's innovative approach. Since its inception, the company has achieved significant milestones in drug development, particularly in advancing treatments for CNS disorders. Their impact is marked by their commitment to addressing unmet medical needs in neurodegenerative diseases, positioning them as a key player in the pharmaceutical industry focused on neuroinflammation.